Allworth Financial’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.36M | Buy |
50,669
+4,111
| +9% | +$197K | 0.01% | 488 |
|
|
2026
Q1 | $2.41M | Buy |
46,558
+46,464
| +49,430% | +$2.37M | 0.01% | 495 |
|
|
2025
Q4 | $4.67K | Buy |
94
+5
| +6% | +$243 | ﹤0.01% | 3752 |
|
|
2025
Q3 | $4.25K | Buy |
89
+24
| +37% | +$966 | ﹤0.01% | 3645 |
|
|
2025
Q2 | $2.05K | Buy |
65
+21
| +48% | +$673 | ﹤0.01% | 3688 |
|
|
2025
Q1 | $1.38K | Sell |
44
-13
| -23% | -$461 | ﹤0.01% | 3349 |
|
|
2024
Q4 | $2.18K | Buy |
57
+17
| +43% | +$599 | ﹤0.01% | 3127 |
|
|
2024
Q3 | $1.25K | Hold |
40
| – | – | ﹤0.01% | 3143 |
|
|
2024
Q2 | $1.21K | Hold |
40
| – | – | ﹤0.01% | 3103 |
|
|
2024
Q1 | $1.36K | Sell |
40
-371
| -90% | -$11K | ﹤0.01% | 2970 |
|
|
2023
Q4 | $11.9K | Sell |
411
-100
| -20% | -$2.65K | ﹤0.01% | 1912 |
|
|
2023
Q3 | $14.1K | Buy |
511
+100
| +24% | +$3.04K | ﹤0.01% | 1723 |
|
|
2023
Q2 | $12.4K | Buy |
411
+323
| +367% | +$11.3K | ﹤0.01% | 1791 |
|
|
2023
Q1 | $3.19K | Buy |
88
+28
| +47% | +$1.08K | ﹤0.01% | 2214 |
|
|
2022
Q4 | $2.14K | Buy |
60
+20
| +50% | +$695 | ﹤0.01% | 2220 |
|
|
2022
Q3 | $1K | Hold |
40
| – | – | ﹤0.01% | 2507 |
|
|
2022
Q2 | $1K | Hold |
40
| – | – | ﹤0.01% | 2264 |
|
|
2022
Q1 | $1K | Hold |
40
| – | – | ﹤0.01% | 2023 |
|
|
2021
Q4 | $1K | Hold |
40
| – | – | ﹤0.01% | 1861 |
|
|
2021
Q3 | $1K | Hold |
40
| – | – | ﹤0.01% | 1802 |
|
|
2021
Q2 | $1K | Hold |
40
| – | – | ﹤0.01% | 1497 |
|
|
2021
Q1 | $1K | Hold |
40
| – | – | ﹤0.01% | 1430 |
|
|
2020
Q4 | $1K | Hold |
40
| – | – | ﹤0.01% | 1293 |
|
|
2020
Q3 | $1K | Hold |
40
| – | – | ﹤0.01% | 1130 |
|
|
2020
Q2 | $1K | Sell |
40
-1
| -2% | -$22 | ﹤0.01% | 1135 |
|
|
2020
Q1 | $1K | Hold |
41
| – | – | ﹤0.01% | 1184 |
|
|
2019
Q4 | $1K | Hold |
41
| – | – | ﹤0.01% | 1011 |
|
|
2019
Q3 | $1K | Hold |
41
| – | – | ﹤0.01% | 918 |
|
|
2019
Q2 | $1K | Hold |
41
| – | – | ﹤0.01% | 906 |
|
|
2019
Q1 | $1K | Buy |
41
+1
| +3% | +$37 | ﹤0.01% | 923 |
|
|
2018
Q4 | $1K | Hold |
40
| – | – | ﹤0.01% | 829 |
|
|
2018
Q3 | $2K | Hold |
40
| – | – | ﹤0.01% | 808 |
|
|
2018
Q2 | $2K | Hold |
40
| – | – | ﹤0.01% | 828 |
|
|
2018
Q1 | $2K | Buy |
+40
| New | +$1.67K | ﹤0.01% | 723 |
|
Other funds holding SUPN
AC
NAMI
SIMG
Allworth Financial's SUPN Position: Q2 2026 in Review
Allworth Financial increased its Supernus Pharmaceuticals (SUPN) stake by 8.8% in Q2 2026, buying an estimated $197K and bringing the position to 50,669 shares worth $2.36M. The position accounts for 0.01% of the portfolio, ranked #488.
Allworth Financial first reported a position in SUPN in Q1 2018 and has held it in 34 quarters since. The position peaked at $2.41M in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- Allworth Financial held 50,669 shares of Supernus Pharmaceuticals worth $2.36M as of Q2 2026.
- Allworth Financial bought 4,111 Supernus Pharmaceuticals shares in Q2 2026, an estimated $197K.
- Supernus Pharmaceuticals made up 0.01% of Allworth Financial's portfolio in Q2 2026, its #488 holding.
- Allworth Financial first reported a position in Supernus Pharmaceuticals in Q1 2018 and has held it in 34 quarters since.
- Allworth Financial's Supernus Pharmaceuticals position peaked at $2.41M in Q1 2026.
- 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.